BackgroundColon cancer (CC) is one of the most common malignancies worldwide. Characterization of new prognostic biomarkers for right-sided CC (RCC) and left-sided CC (LCC) may contribute to improving early detection. An association of human leukocyte antigens class II (HLA-II) with the predisposition to CC was suggested.Aim of the studyWe evaluated the association of DRB1 and DQB1 with the risk of LCC and RCC.Patients and methodsOur study comprised 93 CC patients and 100 healthy controls. Genotyping of HLA class II alleles were performed by the Polymerase Chain Reaction Sequence-Specific Primers (PCR-SSP).ResultsDRB1*03 was positively associated with CC. In contrast, DRB1*11, DRB1*13, DQB1*03, and DQB1*05 were negatively linked to CC. Haplotype analysis revealed that DRB1*04-DQB1*04 and DRB1*09-DQB1*02 were positive, while DRB1*01-DQB1*05, DRB1*04-DQB1*03, DRB1*07-DQB1*02, DRB1*11-DQB1*03, DRB1*11-DQB1*05, and DRB1*13-DQB1*06 were negatively associated with CC. For sigmoid CC, DRB1*13, DRB1*11, and DQB1*05 were negative, while DRB1*04-DQB1*02, and DRB1*07-DQB1*03 were positively associated. DRB1*03 and DRB1*04-DQB1*04 were positive, while DRB1*11 and DQB1*03 were negatively linked to RCC. According to the LCC, DRB1*07, DRB1*11, DQB1*03, DQB1*05, and DRB1*07-DQB1*02 were negative. In contrast, DRB1*09-DQB1*02 was positively associated with LCC. Stratified analysis revealed that DRB1*11 is associated with higher risk of metastasis in CC and sigmoid CC, and tolerance to treatment in RCC. DQB1*03 was associated with lymph-node invasion in CC.ConclusionDRB1 and DQB1 polymorphisms could be used as future biomarkers for the early detection of subjects at a higher risk of developing RCC and LCC, metastasis in sigmoid CC, and tolerance to treatment in RCC.

中文翻译：

---

HLA II 类多态性作为左右结肠癌的预后生物标志物

背景结肠癌（CC）是全世界最常见的恶性肿瘤之一。右侧 CC (RCC) 和左侧 CC (LCC) 新预后生物标志物的表征可能有助于改善早期检测。建议人类白细胞抗原 II 类 (HLA-II) 与 CC 易感性相关。研究目的我们评估了 DRB1 和 DQB1 与 LCC 和 RCC 风险的关联。患者和方法我们的研究包括 93 名 CC 患者和 100 名 CC 患者。健康的控制。采用聚合酶链式反应序列特异性引物(PCR-SSP)对HLA II类等位基因进行基因分型。结果DRB1*03与CC呈正相关。相反，DRB1*11、DRB1*13、DQB1*03和DQB1*05与CC负相关。单倍型分析显示，DRB1*04-DQB1*04和DRB1*09-DQB1*02为阳性，而DRB1*01-DQB1*05、DRB1*04-DQB1*03、DRB1*07-DQB1*02、DRB1*11 -DQB1*03、DRB1*11-DQB1*05 和 DRB1*13-DQB1*06 与 CC 呈负相关。对于 s 状 CC，DRB1*13、DRB1*11 和 DQB1*05 呈负相关，而 DRB1*04-DQB1*02 和 DRB1*07-DQB1*03 呈正相关。DRB1*03和DRB1*04-DQB1*04与RCC呈正相关，而DRB1*11和DQB1*03与RCC呈负相关。根据LCC，DRB1*07、DRB1*11、DQB1*03、DQB1*05和DRB1*07-DQB1*02为阴性。相反，DRB1*09-DQB1*02 与 LCC 呈正相关。分层分析显示，DRB1*11 与 CC 和乙状结肠 CC 的较高转移风险以及 RCC 的治疗耐受性相关。DQB1*03 与 CC 淋巴结侵袭相关。结论 DRB1 和 DQB1 多态性可作为未来的生物标志物，用于早期检测患 RCC 和 LCC、乙状结肠 CC 转移以及 RCC 治疗耐受风险较高的受试者。 。